Abstract
Plasma-derived and recombinant vaccines have been developed to prevent hepatitis B virus infections. Both types of vaccine perform very well with respect to safety, immunogenicity and protective efficacy. The protection afforded by both types of vaccine is satisfactory for at least 5 to 10 years after vaccination, and a further booster dose is not necessary during this period. However, the plasma-derived vaccine is costly to produce and there is an unjustified but prevalent fear that it may be contaminated by potential pathogens. The supply of human plasma for production of the plasma-derived vaccine cannot be assured once use of hepatitis B vaccines becomes universal. It is therefore inevitable that the recombinant vaccine will replace the plasma-derived vaccine. If necessary, both vaccines can be used in combination.
Future directions for hepatitis B vaccine development include: (i) determination of the need for incorporation of pre-S gene products to enhance immunogenicity; (ii) defining a practical strategy to combat the problem of escape mutants after vaccination; and (iii) development of combination vaccines containing other inactivated antigens to allow complete immunisation against several diseases with a minimal number of injections.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Hoofnagle JH. Type B hepatitis: virology, serology and clinical course. Semin Liver Dis 1981 Feb; 1(1): 7–14
Koff RS. Hepatitis B today: clinical and diagnostic overview. Pediatr Infect Dis J 1993 May; 12(5): 428–32
Lee PI, Chang MH, Lee CY, et al. Changes of serum hepatitis B virus DNA and aminotransferase levels during the course of chronic hepatitis B virus infection in children. Hepatology 1990 Oct; 12(4): 657–60
Heermann KH, Goldmann U, Schwartz W, et al. Large surface proteins of hepatitis B virus containing the pre-S sequence. J Virol 1984 Nov; 52(2): 396–402
Miller RH, Kaneko S, Chung CT, et al. Compact organization of the hepatitis B virus genome. Hepatology 1989 Feb; 9(2): 322–7
Robinson WS. Hepadnaviridae and their replication. In: Fields BN, Knipe DM, editors. Fields virology. 2nd rev. ed. New York: Raven Press, 1990: 2137–69
West DJ, Calandra GB, Ellis RW Vaccination of infants and children against hepatitis B. Pediatr Clin North Am 1990 Jun; 37(3): 585–601
Beasley RP, Hwang LY, Lin CC, et al. Incidence of hepatitis B virus infections in preschool children in Taiwan. J Infect Dis 1982 Aug; 146(2): 198–204
Stevens CE, Beasley RP, Tsui JJ, et al. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975 Apr 10; 292(15): 771–4
Davis LG, Weber DJ, Lemon SM. Horizontal transmission of hepatitis B virus. Lancet 1989 Apr 22; I(8643): 889–93
Beasley RP, Trepo C, Stevens CE, et al. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 1977 Feb; 105(2): 94–8
Beasley RP, Hwang LY, Lee CY, et al. Prevention of perinatally transmitted hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983 Nov 12; II(8359): 1099–102
Beasley RP, Hwang LY, Stevens CE, et al. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepatology 1983 Mar-Apr; 3(2): 135–41
Wong VCW, Ip HMH, Reesink HW, et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Lancet 1984 Apr 28; I(8383): 921–6
Xu ZY, Liu CB, Francis DP, et al. Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: preliminary report of a randomized, double-blind placebo-controlled and comparative trial. Pediatrics 1985 Nov; 76(5): 713–8
Lo KJ, Tsai YT, Lee SD, et al. Immunoprophylaxis of infection with hepatitis B virus in infants born to hepatitis B surface antigen-positive carrier mothers. J Infect Dis 1985 Oct; 152(4): 817–22
Alter MJ, Hadler SC, Margolis HS, et al. The changing epidemiology of hepatitis B in the United States. JAMA 1990 Mar 2; 263(9): 1218–22
Beasley RP, Hwang LY, Lin CC, et al. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22707 men in Taiwan. Lancet 1981 Nov 21; II(8256): 1129–33
Chang MH, Chen DS, Hsu HC, et al. Maternal transmission of hepatitis B virus in childhood hepatocellular carcinoma. Cancer 1989 Dec 1; 64(11): 2377–80
Ghendon Y. WHO strategy for the global elimination of new cases of hepatitis B. Vaccine 1990 Mar; 8 Suppl.: 129–33
Greenberg DP. Pediatric experience with recombinant hepatitis B vaccines and relevant safety and immunogenicity studies. Pediatr Infect Dis J 1993 May; 12(5): 438–45
Peterson DL. Isolation and characterization of the major protein and glycoprotein of hepatitis B surface antigen. J Biol Chem 1981 Jul 10; 256(13): 6975–83
Yvonnet B, Coursaget P, Chotard J, et al. Hepatitis B vaccine in infants from an endemic area: long-term anti-HBs persistence and revaccination. J Med Virol 1987 Aug; 22(4): 315–21
Yap I, Guan R, Chan SH. Recombinant DNA hepatitis B vaccine containing Pre-S components of the HBV coat protein — a preliminary study on immunogenicity. Vaccine 1992; 10(7): 439–42
Bucher B, Francioli P, Geudelin B, et al. Immunogenicity of a recombinant pre-S2-containing hepatitis B vaccine versus plasma-derived vaccine administered as a booster. Eur J Clin Microbiol Infect Dis 1994 Mar; 13(3): 212–7
Gerety RJ, Tabor E, Purcell RH, et al. Summary of an international workshop on hepatitis B vaccines. J Infect Dis 1979 Oct; 140(4): 642–8
Waters JA, O’Rourke SM, Richardson SC, et al. Qualitative analysis of the humoral immune response to the a determinant of HBs antigen after inoculation with plasma-derived or recombinant vaccine. J Med Virol 1987 Feb; 21(2): 155–60
Murphy BL, Maynard JE, Le Bouvier GL. Viral subtypes and cross-protection in hepatitis B virus infection of chimpanzees. Intervirology 1974; 3(5-6): 378–81
Steward MW, Sisley BM, Stanley C, et al. Immunity to hepatitis B: analysis of antibody and cellular responses in recipients of a plasma-derived vaccine using synthetic peptides mimicking S and pre-S regions. Clin Exp Immunol 1988 Jan; 71(1): 19–25
Emini EA, Ellis RW, Miller WJ, et al. Production and immuno-logical analysis of recombinant hepatitis B vaccine. J Infect 1986 Jul; 13Suppl. A: 3–9
Zajac BA, West DJ, McAleer WJ, et al. Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. J Infect 1986 Jul; 13Suppl. A: 39–45
Centers for Disease Control. Update on hepatitis B prevention: recommendations of the Immunization Practices Advisory Committee. Ann Intern Med 1987 Sep; 107(3): 353–7
André FE. Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine 1990 Mar; 8 Suppl.: 74–8
Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high risk population in the United States. N Engl J Med 1980 Oct 9; 303(15): 833–41
Francis DP, Hadler SC, Thompson SE, et al. Prevention of hepatitis B with vaccine: report from the Centers for Disease Control multi-center efficacy trial among homosexual men. Ann Intern Med 1982 Sep; 97(3): 362–6
André FE, Path FRC. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med 1989 Sep 4; 87Suppl. 3A: 14–20
Francis DP, Feorino PM, McDougal J, et al. The safety of hepatitis B vaccine. Inactivation of the AIDS virus during routine vaccine manufacture. JAMA 1986 Aug 15; 256(7): 869–72
Wiedermann G, Scheiner O, Ambrosch F, et al. Lack of induction of IgE and IgG antibodies to yeast in humans immunized with recombinant hepatitis B vaccines. Int Arch Allergy Appl Immunol 1988; 85(1): 130–2
West DJ. Clinical experience with hepatitis B vaccine. Am J Infect Control 1989 Jun; 17(3): 172–80
Stevens CE, Taylor PE, Tong MJ, et al. Prevention of perinatal hepatitis B virus infection with hepatitis B immune globulin and hepatitis B vaccine. In: Zuckerman AJ, editor. Viral hepatitis and liver disease. New York: Alan R Liss, 1988; 982–8
Hwang LY, Beasley RP, Lee CY, et al. Prevention of perinatally transmitted hepatitis B virus infection with hepatitis B immune globulin and/or HB vaccine. In: Vyas GN, Dienstag JL, Hoofnagle JH, editors. Viral hepatitis and liver disease. Orlando (FL): Grune & Stratton, 1984: 678
Pongpipat D, Suvatte V, Assateerawatts A. Hepatitis B immunization in high risk neonates born from HBsAg positive mothers: comparison between plasma derived and recombinant DNA vaccine. Asian Pac J Allergy Immunol 1989 Jun; 7(1): 37–40
Stevens CE, Toy PT, Taylor PE, et al. Prospects for control of hepatitis B virus infection: implications of childhood vaccination and long-term protection. Pediatrics 1992 Jul; 90 (1 Pt 2): 170–3
Poovorawan Y, Sanpavat S, Pongpunglert W, et al. Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers. Pediatr Infect Dis J 1992 Oct; 11(10): 816–21
Lee CY, Huang LM, Chang MH, et al. The protective efficacy of recombinant hepatitis B vaccine in newborn infants of hepatitis B e antigen-positive-hepatitis B surface antigen carrier mothers. Pediatr Infect Dis J 1991 Apr; 10(4): 299–303
Lee CY, Lee PI, Huang LM, et al. A simplified schedule to integrate the hepatitis B vaccine into an expanded program of immunization in endemic countries. J Pediatr 1997 Jun; 130(6): 981–6
André FE, Zuckerman AJ. Review: protective efficacy of hepatitis B vaccines in neonates. J Med Virol 1994 Oct; 44(2): 144–51
Burk RD, Hwang LY, Ho GYF, et al. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J Infect Dis 1994 Dec; 170(6): 1418–23
Lee CY, Hwang LY, Beasley RP. Low-dose hepatitis B vaccine [letter]. Lancet 1989; Oct 7; II(8667): 860–1
Szmuness W, Stevens CE, Zang EA, et al. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B). A final report. Hepatology 1981 Sep–Oct; 1(5): 377–85
Coursaget P, Yvonnet B, Chotard J, et al. Seven-year study of hepatitis B vaccine efficacy in infants from an endemic area (Senegal). Lancet 1986 Nov 15; II(8516): 1143–5
Hadler SC, Francis DP, Maynard JE, et al. Long-term immuno-genicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986 Jul 24; 315(4): 209–14
Taylor PE, Stevens CE. Persistence of antibody to hepatitis B surface antigen after vaccination with hepatitis B vaccine. In: Zuckerman AJ, editor. Viral hepatitis and liver disease. New York: Alan R Liss, 1988: 995–7
Zuckerman JN. Nonresponse to hepatitis B vaccines and the kinetics of anti-HBs production. J Med Virol 1996 Dec; 50(4): 283–8
Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection. N Engl J Med 1982 Dec 9; 307(24): 1481–6
Kohler H, Arnold W, Renschin G, et al. Active hepatitis B vaccination of dialysis patients and medical staff. Kidney Int 1984 Jan; 25(1): 124–8
Lai CL, Wong BCY, Yeoh EK, et al. Five-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs. plasma-derived vaccine in children: immunogenicity and anamnestic responses. Hepatology 1993 Oct; 18(4): 763–7
Inskip HM, Hall AJ, Chotard J, et al. Hepatitis B vaccine in the Gambian Expanded Programme on Immunization: factors influencing antibody response. Int J Epidemiol 1991 Sep; 20(3): 764–9
Clements ML, Miskovsky E, Davidson M, et al. Effect of age on the immunogenicity of yeast recombinant hepatitis B vaccines containing surface antigen (S) or PreS2 + S antigens. J Infect Dis 1994 Sep; 170(3): 510–6
Collier AC, Corey L, Murphy VL, et al. Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Ann Intern Med 1988 Jul 15; 109(2): 101–5
Shaw Jr FE, Guess HA, Roets JM, et al. Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. Vaccine 1989 Oct; 7(5): 425–30
Weber DJ, Rutala WA, Samsa GP, et al. Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. JAMA 1985 Dec 13; 254(22): 3187–9
Alper CA, Kruskall MS, Marcus-Bagley D, et al. Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med 1989 Sep 14; 321(11): 708–12
Craven DE, Awdeh ZL, Kunches LM, et al. Nonresponsiveness to hepatitis B vaccine in health care workers: results of revaccination and genetic typings. Ann Intern Med 1986 Sep; 105(3): 356–60
Hsu HY, Chang MH, Ho HN, et al. Association of HLA-DR14-DR52 with low responsiveness to hepatitis B vaccine in Chinese residents in Taiwan. Vaccine 1993 Nov; 11(14): 1437–40
Katkov WN, Dienstag JL. Hepatitis vaccines. Gastroenterol Clin North Am 1995 Mar; 24(1): 147–59
Milich DR, McLachlan A, Thornton GB, et al. Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site. Nature 1987 Oct 8-14; 329(6139): 547–9
Centers for Disease Control. Recommendations of the Immunization Practices Advisory Committee update on hepatitis B prevention. JAMA 1987 Jul; 258(4): 437–49
Most J, Larcher C, Vogetseder W, et al. Recombinant versus plasma-derived hepatitis B vaccine: comparison of immunogenicity in medical students. Vaccine 1992; 10(11): 740–1
Grosheide PM, del Canho R, Voogd M, et al. Anti-HBs levels in infants of hepatitis B carrier mothers after delayed active immunization with recombinant vaccine concomitant with DTP-polio vaccine: is there need for a second dose of HBIg? Vaccine 1994 Sep; 12(12): 1059–63
Panda SK, Ramesh R, Rao KVS, et al. Comparative evaluation of the immunogenicity of yeast-derived (recombinant) and plasma-derived hepatitis B vaccine in infants. J Med Virol 1991 Dec; 35(4): 297–301
Jilg W, Lorbeer B, Schmidt M, et al. Clinical evaluation of a recombinant hepatitis B vaccine. Lancet 1984 Nov 24; II(8413): 1174–5
Cheng KF, Chang MH, Lee CY, et al. Response to supplementary vaccination with recombinant or plasma hepatitis B vaccine in healthy non-responding children. Vaccine 1994 Aug; 12(10): 899–902
Tan KL, Goh KT, Oon CJ, et al. Immunogenicity of recombinant yeast-derived hepatitis B vaccine in nonresponders to perinatal immunization. JAMA 1994 Mar 16; 271(11): 859–61
Chotard J, Inskip HM, Hall AJ, et al. The Gambian hepatitis intervention study: follow-up of a cohort of children vaccinated against hepatitis B.J Infect Dis 1992 Oct; 166(4): 764–8
Lo KJ, Lee SD, Tsai YT, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in infants born to HBeAg-positive HBsAg-carrier mothers. Hepatology 1988 Nov–Dec; 8(6): 1647–50
Jilg W, Schmidt M, Deinhardt F. Persistence of specific antibodies after hepatitis B vaccination. J Hepatol 1988 Apr; 6(2): 201–7
Resti M, Azzari C, Rossi ME, et al. Five-year follow-up of vaccination against hepatitis B virus in newborns vaccinated with areduced number of doses. Vaccine 1991 Jan; 9(1): 15–8
Chan CY, Lee SD, Tsai YT, et al. Long-term follow-up of hepatitis B vaccination in susceptible hospital personnel. J Gastroenterol Hepatol 1992 May–Jun; 7(3): 266–9
Lee CY, Beasley RP, Hwang LY. Long-term follow-up of immunogenicity and efficacy of hepatitis B vaccination in high-risk infants. In: Sung JL, Chen DS, editors. Viral hepatitis and hepatocellular carcinoma. Proceedings of the Second International Symposium on Viral Hepatitis and Hepatocellular Carcinoma; 1988 Dec 7–9; Hong Kong. Amsterdam: Excerpta Medica, 1990: 427–30
Gonzalez ML, Gonzalez JB, Salva F, et al. A 7-year follow-up of newborns vaccinated against hepatitis B. Vaccine 1993; 11(10): 1033–6
Delage G, Rémy-Prince S, Montplaisir S. Combined active-passive immunization against the hepatitis B virus: five-year follow-up of children born to hepatitis B surface antigen-positive mothers. Pediatr Infect Dis J 1993 Feb; 12(2): 126–30
Moyes CD, Milne A, Waldon J. Very low dose hepatitis B vaccination in the newborn: anamnestic response to booster at four years. J Med Virol 1990 Mar; 30(3): 216–8
Coursaget P, Leboulleux D, Soumare M, et al. Twelve-year follow-up study of hepatitis B immunization of Senegalese infants. J Hepatol 1994 Aug; 21(2): 250–4
Ding L, Zhang M, Wang Y, et al. A 9-year follow-up study of immunogenicity and long-term efficacy of plasma-derived hepatitis B vaccine in high-risk Chinese neonates. Clin Infect Dis 1993 Sep; 17(3): 475–9
Lee PI, Lee CY, Huang LM, et al. Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen. J Pediatr 1995 May; 126 (5 Pt 1): 716–21
Whittle HC, Inskip H, Hall AJ, et al. Vaccination against hepatitis B and protection against chronic viral carriage in The Gambia. Lancet 1991 Mar 30; 337(8744): 747–50
Zhang M, Lie K, Ding L, et al. Duration and efficacy of immune response to hepatitis B vaccine in high-risk Chinese adolescents. Clin Infect Dis 1993 Jan; 16(1): 165–7
Goh KT, Tan KL, Kong KH, et al. Comparison of the immune response of four different dosages of a yeast-recombinant hepatitis B vaccine in Singapore children: a four-year follow-up study. Bull WHO 1992; 70(2): 233–9
Trivello R, Chiaramonte M, Ngatchu T, et al. Persistence of anti-HBs antibodies in health care personnel vaccinated with plasma-derived hepatitis B vaccine and response to recombinant DNA HB booster vaccine. Vaccine 1995 Feb; 13(2): 139–41
Coursaget P, Yvonnet B, Gilks WR, et al. Scheduling of revaccination against hepatitis B virus. Lancet 1991 May 18; 337(8751): 1180–3
Grosheide PM, del Canho R, Heijtink RA, et al. Passive-active immunization in infants of hepatitis Be antigen-positive mothers: comparison of the efficacy of early and delayed active immunization. Am J Dis Child 1993 Dec; 147(12): 1316–20
Wainwright RB, McMahon BJ, Bulkow LR, et al. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population. JAMA 1989 Apr 28; 261(16): 2362–6
Tabor E, Cairns J, Gerety RJ, et al. Nine-year follow-up study of a plasma-derived hepatitis B vaccine in a rural African setting. J Med Virol 1993 Jul 3; 40(3): 204–9
Tsen YJ, Chang MH, Hsu HY, et al. Seroprevalence of hepatitis B virus infection in children in Taipei, 1989: five years after a mass hepatitis B vaccination program. J Med Virol 1991 Jun; 34(2): 96–9
Leroux-Roels G, Van Hecke E, Michielsen W, et al. Correlation between in vivo humoral and in vitro cellular immune responses following immunization with hepatitis B surface antigen (HBsAg) vaccines. Vaccine 1994 Jul; 12(9): 812–8
Hou MC, Wu JC, Kuo BIT, et al. Heterosexual transmission as the most common route of acute hepatitis B virus infection among adults in Taiwan — the importance of extending vaccination to susceptible adults. J Infect Dis 1993 Apr; 167(4): 938–41
Alexander PG, Johnson R, Williams WW, et al. Hepatitis B vaccination programs for health care personnel in US hospitals. Public Health Rep 1990 Nov–Dec; 105(6): 610–6
Chen DS, Hsu NH, Sung JL, et al. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. JAMA 1987 May 15; 257(19): 2597–603
Chen HL, Chang MH, Ni YH, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 1996 Sep 18; 276(11): 906–8
Pearl KK, Ortiz AA, Pearl W. Efficacy of immunization with a combination of serum and recombinant hepatitis B vaccines. Infect Control Hosp Epidemiol 1993 Aug; 14(8): 476–8
Lee PI, Lee CY, Huang LM, et al. A follow-up study of combined vaccination with plasma-derived and recombinant hepatitis B vaccines in infants. Vaccine 1995 Dec; 13(17): 1685–9
Maupas Ph, Goudeau A, Coursaget P, et al. Immunization against hepatitis B in man: a pilot study of two years’ duration. In: Vyas GN, Cohen SN, Schmid R, editors. Viral hepatitis: a contemporary assessment of etiology, epidemiology, pathogenesis and prevention. Philadelphia: Franklin Institute Press, 1979: 359–556
Suzuki H, Iino S, Shiraki K, et al. Safety and efficacy of a recombinant yeast-derived pre-S2+S-containing hepatitis B vaccine (TGP-943): phase 1, 2 and 3 clinical testing. Vaccine 1994 Sep; 12(12): 1090–6
Emini EA, Larson V, Eichberg J, et al. Protective effect of a synthetic peptide comprising the compatible preS2 region of the hepatitis B virus surface protein. J Med Virol 1989 May; 28(1): 7–12
Milich DR, Thornton GB, Neurath AR, et al. Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science 1985 Jun 7; 228(4704): 1195–9
Gerlich W, Deepen R, Heermann KH, et al. Protective potential of hepatitis B virus antigens other than the S gene protein. Vaccine 1990 Mar; 8Suppl.: 63–8
Milich DR, Chisari FV. Genetic regulation of the immune response to hepatitis B surface antigen (HBsAg). I. H-2 restriction of the murine humoral response to the a and d determinants of HBsAg. J Immunol 1982 Jul; 129(1): 320–5
Milich DR, Leroux-Roels GG, Chisari FV. Genetic regulation of the immune response to hepatitis B surface antigen (HBsAg). II. Qualitative characteristics of the humoral immune response to the a, d, and y determinants of HBsAg. J Immunol 1983 Mar; 130(3): 1395–400
Milich DR, McNamara MK, McLachlan A, et al. Distinct H2-linked regulation of T-cell responses to the pre-S and S regions of the same hepatitis B surface antigen polypeptide allows circumvention of non-responsiveness to the S region. Proc Natl Acad Sci USA 1985 Dec; 82(23): 8168–72
Milich DR, McLachlan A, Chisari FV, et al. Immune response to the pre-S(l) region of hepatitis B surface antigen (HBsAg): a pre-S(l)-specific T cell response can bypass nonresponsiveness to the pre-S(2) and S regions of the HBsAg. J Immunol 1986 Jul 1; 137(1): 315–22
Zuckerman JN, Sabin C, Craig FM, et al. Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomised double blind dose-response study. BMJ 1997 Feb 1; 314(7077): 329–33
Brown SE, Howard CR, Zuckerman AJ, et al. Affinity of antibody response in man to hepatitis B vaccine determined with synthetic peptides. Lancet 1984 M 28; II(8396): 184–7
Howard CR, Stirk HJ, Brown SE, et al. Towards the development of synthetic hepatitis B vaccines. In: Zuckerman AJ, editor. Viral hepatitis and liver disease. New York: Alan R Liss, 1988: 1094–101
Ashton-Rickardt PG, Murray K. Mutants of the hepatitis B virus surface antigen that define some antigenically essential residues in the immunodominant a region. J Med Virol 1989 (Nov); 29(3): 196–203
Bruce SA, Murray K. Mutations of some critical amino acid residues in the hepatitis B virus surface antigen. J Med Virol 1995 Jun; 46(2): 157–61
Carman WF, Zanetti AR, Karayiannis P, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990 Aug 11; 336(8711): 325–9
Okamoto H, Yano K, Nozaki Y, et al. Mutations within the S gene of hepatitis B virus transmitted from mothers to babies immunized with hepatitis B immune globulin and vaccine. Pediatr Res 1992 Sep; 32(3): 264–8
Oon CJ, Lim GK, Ye Z, et al. Molecular epidemiology of hepatitis B virus vaccine variants in Singapore. Vaccine 1995; 13(8): 699–702
Lee PI, Chang LY, Lee CY, et al. Detection of hepatitis B surface gene mutation in carrier children with or without immunoprophylaxis at birth. J Infect Dis 1997 Aug; 176(2): 427–30
Karthigesu VD, Allison LMC, Fortuin M, et al. A novel hepatitis B virus variant in the sera of immunized children. J Gen Virol 1994 Feb; 75: 443–8
Fujii H, Moriyama K, Sakamoto N, et al. Gly145to Arg substitution in HBs antigen of immune escape mutant of hepatitis B virus. Biochem Biophys Res Commun 1992 May 15; 184(3): 1152–7
Hino K, Okuda M, Hashimoto O, et al. Glycine-to-arginine substitution at codon 145 of HBsAg in two infants born to hepatitis B e antigen-positive carrier. Dig Dis Sci 1995 Mar; 40(3): 566–70
Yamamoto K, Horikita M, Tsuda F, et al. Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen. J Virol 1994 Apr; 68(4): 2671–6
Wallace LA, Echevarria JE, Echevarria JM, et al. Molecular characterization of envelope antigenic variants of hepatitis B virus from Spain. J Infect Dis 1994 Nov; 170(5): 1300–3
Zuckerman AJ. Developing new hepatitis B immunisation strategies. Gut 1996; 38Suppl. 2: 60–2
Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med 1997 Jan 16; 336(3): 196–204
Da Villa G, Piazza M, Iorio R, et al. Apilot model of vaccination against hepatitis B virus suitable for mass vaccination campaigns in hyperendemic areas. J Med Virol 1992 Apr; 36(4): 274–8
West DJ, Calandra GB, Hesley TM, et al. Control of hepatitis B through routine immunization of infants: the need for flexible schedules and new combination vaccine formulations. Vaccine 1993; 11Suppl. 1: 21–7
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lee, PI., Lee, CY. Practical Considerations in Converting from Plasma-Derived to Recombinant Hepatitis B Vaccines. BioDrugs 10, 11–25 (1998). https://doi.org/10.2165/00063030-199810010-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00063030-199810010-00002